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http:WHAT THIS PAPER ADDS
This paper presents the largest series of patients with true venous aneurysm of an arteriovenous ﬁstula.
Reinforced aneurysmorrhaphy with external mesh prosthesis is an effective method suitable for surgical
treatment of symptomatic true aneurysmal haemodialysis arteriovenous access, with an excellent patency rate,
minimal infection rate, and no aneurysmal recurrence. It is appropriate for patients with high-ﬂow aneurysmal
ﬁstula.Objective: In 2008, a new technique of reinforced aneurysmorrhaphy with a polyester mesh tube for salvaging
true aneurysmal arteriovenous (AV) haemodialysis access was described by us. In this study, the long-term
patency and complication rates associated with this procedure were analysed, and the effect of reinforced
aneurysmorrhaphy on high-ﬂow vascular access was assessed.
Methods: This was a retrospective non-randomised study with prospectively collected data performed at a single
centre. Patients with true aneurysmal haemodialysis AV access who underwent aneurysmorrhaphy with external
mesh prosthesis between March 2007 and October 2012 were included. Clinical assessment and duplex
ultrasound were performed preoperatively, 1, 3, and 12 months postoperatively, and annually thereafter.
Results: Data from 62 patients (median age 60 years, range 28e81 years; 63% men) were analysed. The
commonest indication was high-ﬂow vascular access associated with the risk of high output cardiac failure (24
patients, 39%). The mean follow-up time was 14.66  12.80 months. Primary patency rates at 6 and 12 months
were 86% and 79% respectively. Assisted primary patency rates at 6 and 12 months were 89% and 80%
respectively. In 23 patients (96%) operated on for high-ﬂow vascular access, decreased vascular access ﬂow was
observed after the procedure. The average ﬂow reduction after aneurysmorrhaphy was 2,197 mL/minute.
Postoperative bleeding and infection necessitating surgical revision occurred in three (4.8%) and three (4.8%)
patients respectively.
Conclusions: Reinforced aneurysmorrhaphy with an external mesh prosthesis is an effective method for treating
true aneurysmal haemodialysis AV access, with excellent long-term patency and minimal complications due to
infection.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2014.01.010as high as 30%.1 The clinical presentation of aneurysm is
often asymptomatic, does not require any intervention, and
can be managed by abandoning cannulation.2 Treatment is
indicated in cases of symptomatic aneurysm presenting
with active bleeding, imminent risk of rupture, ﬁstula
infection, excessive ﬁstula blood ﬂow, or signiﬁcant
cosmetic issues.3 Although several types of surgical and
endovascular procedures have been described, clinical
guidelines are limited in terms of when and how to inter-
vene.2,4 In 2008, a new technique for salvaging a true
aneurysmal AVF by reinforced aneurysmorrhaphy with a
mesh tube was described by us.5 In this report, data on
Figure 1. Reinforced aneurysmorrhaphy technique. (A) Venous arm of the ﬁstula mobilised up to the non-dilated part of the vein; (B)
resection of aneurysms using BalRok clamp; (C) vein wall remaining after aneurysm resection sewn with a continuous running suture; (D)
repaired vein after aneurysmorrhaphy; (E) implantation of external mesh prosthesis; (F) repaired vein tunnelled subcutaneously and re-
anastomosis.
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 4 p. 444e450 April/2014 445long-term patency and complication rates with this tech-
nique are presented, and the effect of this technique on
high-ﬂow vascular access is assessed.
MATERIAL AND METHODS
Study population
Between March 2007 and October 2012 this department
treated 551 patients for arteriovenous (AV) access creation
or AV access complications, including patients with true
aneurysmal AVF. Demographics, pre- and perioperative, and
follow-up data were recorded prospectively in an institution
database. Patients with true aneurysmal haemodialysis AVF
who had been treated by reinforced aneurysmorrhaphy
were identiﬁed. The case records were analysed retro-
spectively. Informed consent was obtained from all patients
preoperatively.Preoperative assessment
Duplex ultrasound was used to assess the diameter and
length of the aneurysm, the presence of intraluminal
thrombus and stenosis, the blood ﬂow in the brachial artery,
and the size of the AV anastomosis, and to exclude the
possibility of central vein stenosis. When central vein ste-
nosis was suspected, ﬁstulography was performed. Patients
with high-ﬂow access (deﬁned as ﬂow in the brachial artery
>2,500 mL/minute) were referred for cardiology examina-
tion to assess the presence of hyperkinetic circulation. Hy-
perkinetic circulation was deﬁned as a cardiac index of more
than 3.9 L/minute/m2, measured by transthoracic echo-
cardiography. High output cardiac failure was deﬁned as a
combination of hyperkinetic circulation with the physical
ﬁndings of systemic venous or pulmonary congestion.6 All
patients with an aneurysmal AVF with chronic kidney dis-
ease (CKD) stage 1e3 at the time of the study who had had
a previous renal transplant (AVF was created prior to renal
transplant) were treated by AVF ligation and creation of
new access at the time of the deterioration. However, the
deﬁnitive indication for the salvage of the AVF was alwaysdiscussed with nephrologists in all patients, and the actual
renal function and the status of the kidney transplant (the
history of rejection and delayed graft function with the type
of organ donor) was considered. If the risk of deterioration
of renal function was considered high, salvage of the AVF by
aneurysmorrhaphy was indicated.Reinforced aneurysmorrhaphy technique
All procedures were performed by two surgeons. Patients
were given general or locoregional anaesthesia. Intravenous
prophylactic antibiotics (cefazolin 1 g) were administered 30
minutes before surgery. Small skin incisions (3e5 cm) were
made at the site of the AV anastomosis. Another incision
(3e5 cm) was made along the whole length of the aneu-
rysmal vein.
The anastomosis was dissected, and the aneurysmal ﬁs-
tula vein was mobilised up to the non-dilated part (Fig. 1A).
Heparin (5,000e10,000 IU) was administered. The supplying
artery and non-dilated vein above the proximal aneurysm
were clamped. Immediately beyond the AV anastomosis,
the vein was disconnected from the artery, and the aneu-
rysmal sacs were resected (Fig. 1B). To resect the aneu-
rysmal vein, a metal tube (5, 6, or 7 mm in diameter) was
inserted into the vein. The vein wall remaining after aneu-
rysm resection was sewn with a continuous running suture
(Fig. 1C,D). From February 2011 onward, aneurysms were
resected using a special instrument developed by our team,
called the BalRok clamp.7
The repaired vein was scaffolded with an external mesh
prosthesis (ProVena, BBraun Medical, Melsungen, Ger-
many) with a diameter 1 mm larger than the metal tube of
the BalRok clamp (Fig. 1E). The meshed vein was tunnelled
subcutaneously to the previous anastomosis site, and re-
anastomosis was performed (Fig. 1F). Heparin was neu-
tralised by an adequate dose of protamine sulphate and,
upon checking haemostasis, two Redon drains were placed
before wound closure. In the postoperative period, all pa-
tients were administered 100 mg of acetylsalicylic acid.
Table 1. Patient characteristics.
Variable n (%) or median (range)
Demography
Age (y) 60 (28e81)
Men 39 (63)
Hypertension 57 (92)
Diabetes 10 (16)
Tobacco use 14 (23)
Coronary artery disease 6 (10)
Stroke/TIA 2 (3)
Peripheral arterial disease 1.0 (1.5)
Previous renal transplantation 46 (74)
Underlying renal disease
Glomerulonephritis 24 (39)
Polycystic kidney 13 (21)
Tubulointerstitial nephritis 11 (18)
Renal vascular disease 10 (16)
Unknown 3.0 (4.5)
Diabetic nephropathy 1.0 (1.5)
CKD stage
1 1.0 (1.5)
2 13 (21)
3 22 (35)
4 7 (11)
5 19 (30)
Note. TIA ¼ transient ischaemic attack; CKD ¼ chronic kidney
disease.
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Clinical assessment with duplex ultrasound for evaluation of
patency and access ﬂow was performed at 1, 3, and 12
months postoperatively and yearly thereafter. Patients with
persistent high ﬂow postoperatively were investigated
every 3 months. In the case of stenosis or inadequate ﬂow,
ﬁstulography was performed.Endpoints and deﬁnitions
The primary endpoint was primary patency rate after
aneurysmorrhaphy. Secondary endpoints included assisted
primary and secondary patency, procedure-related compli-
cations, and the effect of aneurysmorrhaphy in high-ﬂow
AVF. In this report, patency is presented according to the
recommended standards for reporting AV haemodialysis
accesses.8 An aneurysmal AVF was deﬁned as dilatation
having a threefold larger diameter than the vessel segmentsTable 2. The inﬂuence of various risk factors on primary patency
rates.
Variable Odds ratio (95% CI) p
Age 1.02 (0.99e1.05) .15
Women 1.15 (0.62e2.15) .67
Hypertension 1.12 (0.27e4.69) .88
Diabetes 1.04 (0.45e2.37) .93
Tobacco use 0.52 (0.22e1.25) .14
Coronary artery disease 1.92 (0.99e3.74) .06
Peripheral arterial disease 1.79 (0.89e3.60) .1
Note. CI ¼ conﬁdence interval.immediately upstream and downstream from the access
site.16 Technical success was deﬁned by the presence of
thrill at the end of the procedure. Stenosis was deﬁned as a
more than 50% reduction in diameter, as proven by ultra-
sound9 or ﬁstulography. Failed AVF due to thrombosis was
detected by clinical assessment and ultrasound. Low and
high ﬂow were deﬁned as <400 mL/minute and
>2,500 mL/minute respectively.Statistical analysis
Descriptive statistics are expressed as the mean  SD,
median (interquartile range [IQR]) or frequency (%). The
effect of the operation on ﬂow was assessed using the
paired t test. Categorical variables were compared using the
chi-square test. Patency analyses were performed using the
KaplaneMeier method. Differences between groups were
determined with the log-rank test. A Cox proportional
hazards model was used to assess the inﬂuence of different
parameters on patency. Calculations were done using SPSS
version 20 (IBM, Somers, NY, USA). A two-sided p-value
0.05 was considered statistically signiﬁcant.
RESULTS
During the study period, 62 patients were treated, including
39 men (63%), with a median age of 60 years (range 28e81
years). Other patient characteristics are shown in Table 1.
Hypertension and diabetes were present in 57 (92%) and 10
(16%) patients respectively. In the multivariate analysis,
these risk factors did not affect the patency rate (Table 2).
Forty AVFs (65%) were in the forearm, and the other 22
AVFs (35%) were in the upper arm. Other AVF character-
istics are shown in Table 3. Indication for treatment was the
presence of true multiple (concomitant) AVF aneurysms
associated with another indication (Table 3). The most
common additional indication was high-ﬂow AVF (24 pa-
tients, 39%), with a mean ﬂow rate of
3,968.4  1,923.8 mL/minute. Two patients had chronic
heart failure due to hyperkinetic circulation, as diagnosed
by a cardiologist, despite having AVF volume ﬂows of 1,600
and 1,800 mL/minute respectively.
The mean operative time was 138  37 (80e240) mi-
nutes. The diameter of the external mesh prosthesis used
was 6 mm in nine patients (14%), 7 mm in 45 patients
(73%), and 8 mm in eight patients (13%). The BalRok clamp
was used in 37 patients (60%). Technical success was ob-
tained in all patients, with a median postoperative hospital
stay of 3 (1e23) days. In patients on haemodialysis, median
time to use of the AVF was 4 weeks. The mean follow-up
time was 14.6  12.8 (0e67) months, and follow-up was
completed by all patients.
The primary patency rates at 6 and 12 months were 86%
and 79% respectively. Two patients required percutaneous
angioplasty of central vein stenosis; however, the vein le-
sions were not related to the part of the vein that had
undergone aneurysmorrhaphy. Six patients (9.6%) under-
went angioplasty for stenosis of the vein after aneur-
ysmorrhaphy, with immediate technical success. One
Figure 2. KaplaneMeier curve showing primary, primary assisted,
and secondary patency rates after aneurysmorrhaphy.
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occlusion of the ulnar artery. Repositioning of the anasto-
mosis was performed at 16 months postoperatively. Assis-
ted primary patency rates at 6 and 12 months were 89%
and 80% respectively. Two late AVF thrombosis events in
one patient, which occurred at 4 and 8 months post-
operatively, were managed surgically. Secondary patency
rates at 6 and 12 months were 91% and 80% respectively.
KaplaneMeier curves for patency rates are shown in Fig. 2.
Patency rates did not differ between forearm and upper
arm operations (p ¼ .50).
In 24 patients (39%), aneurysmorrhaphy was performed
for high-ﬂow AVF. In all but one of these patients ﬂow
through the AVF was signiﬁcantly decreased after the
operation (3,968.4  1,923.8 mL/minute before vs.
1,771.1  843.4 mL/minute after operation, p < .001). The
mean ﬂow reduction was 2,197 mL/minute (Fig. 3). Two
patients with high-ﬂow ﬁstulae underwent reoperation for
an inadequate reduction in ﬂow. In the ﬁrst patient, ﬂow
decreased by >4,500 mL/minute, but it increased during
the follow-up period of 9 months to the preoperative value
(6,000 mL/minute). Reduction of the anastomosis was
performed 11 months after the primary operation. Post-
operatively, ﬂow decreased again, but during the next 9
months it increased to >2,500 mL/minute. The patient was
in CKD stage 2. Because of signs of cardiac failure, ligation
was performed 21 months after the primary surgery. In the
second patient, ﬂow decreased postoperatively >1,000 mL/
minute; however, the ﬂow rate remained >2,500 mL/min-
ute. This patient was successfully treated 13 months after
the primary surgery by a further reduction of the
anastomosis.
Postoperative bleeding necessitating surgical revision
occurred in three patients (4.8%). Infection of the prosthesisTable 3. Arteriovenous ﬁstula (AVF) characteristics and surgical
indications.
Variable n (%)
Type of AVF
Forearm
Radial-cephalic ﬁstula 39 (63)
Ulnar-cephalic ﬁstula 1 (2)
Upper arm
Brachial-cephalic ﬁstula 15 (24)
Brachial-basilic ﬁstula 7 (11)
AVF characteristics Mean  SD (range)
Number of aneurysms 2.33  0.57 (1.00e3.00)
Maximum aneurysm
diameter (mm)
34.47  7.33 (20.00e55.00)
AVF survival (y) 9.03  6.07 (2.00e29.00)
Indication n (%)
High-ﬂow AVF 24 (39)
Pain overlaying skin 15 (24)
Progressive enlargement 12 (19)
Bleeding 5 (8)
Steal syndrome 3.0 (4.5)
Stenosis 2 (3)
Thrombosis 1.0 (1.5)(with Staphylococcus aureus) occurred in one patient 30
days after surgery. Explantation of the AVF was performed.
One patient developed a phlegmon 1 week after surgery;
antibiotics were administered, with improvement of the
condition. Thrombosis of the AVF with concomitant phleg-
mon and pain then developed 2 months postoperatively;
conservative treatment was unsuccessful, and AVF resec-
tion with mesh removal was performed 3 months after the
primary surgery (culture ﬁndings negative). Another patient
developed small necrotic skin lesions overlaying the AVF
with mesh exposure 3 months after surgery (culture ﬁnd-
ings were negative). In this case, the AVF was resected andFigure 3. Arteriovenous ﬁstula (AVF) ﬂow rate before and after
aneurysmorrhaphy in the subgroup of patients with high-ﬂow AVF.
Table 4. Postoperative complications.
Variable n (%) n (%) n (%)
<30 d 30 d Total
Haematoma
without revision
7 (11) 0 7 (11)
Bleeding with revision 3.0 (4.5) 0 3.0 (4.5)
Infection of prosthesis 1.0 (1.5) 2 (3) 3.0 (4.5)
Re-operation for high ﬂow 0 2 (3) 2 (3)
Non-fatal cardiac 0 2 (3) 2 (3)
Stoke/TIA 0 1.0 (1.5) 1.0 (1.5)
Death 1.0 (1.5) 7.0 (11) 8.0 (12.5)
Note. TIA ¼ transient ischaemic attack.
448 S. Rokosný et al.a new AVF was performed in the same session. Although
the culture ﬁndings were negative in these two cases, both
contributed to the infectious complication rate (three pa-
tients, 4.8%).
There was one perioperative and there were eight late
deaths that were unrelated to the aneurysmorrhaphy pro-
cedure. Complications are listed in Table 4. During follow-up
(14.66  12.80 months) we did not record any recurrence
of aneurysm of the AVF.DISCUSSION
Although autogenous AV access for haemodialysis is a
routine surgical procedure, the long-term patency is limited,
aneurysmal enlargement is not uncommon, and complica-
tions can be severe. AV access increases cardiac output,
which may lead to eccentric left ventricular hypertrophy,
which is a key factor in the development of congestive heart
failure in haemodialysis patients.6 While the exact patho-
genesis of aneurysmal dilatation remains unclear, several
mechanisms have been proposed. Frequently discussed are
the effects of repeat needle puncture for dialysis,10 hae-
modynamic factors, such as pre- and post-aneurysm ste-
notic lesions,2 and the effects of hypertension or
immunosuppression.11
The KDOQI vascular access guidelines recommend that
uncomplicated aneurysms be managed by abandoning
cannulation of the aneurysmal areas in favour of healthier
ﬁstula segments.2 Recently, the buttonhole technique was
recommended as a method to reduce existing aneurysm
enlargement.12 Numerous case reports and small case-
series of aneurysmal AVF treatment have been published.
Several techniques have been proposed, including aneu-
rysm resection with/without graft interposition,13e14 partial
aneurysmectomy,3 plication, venorrhaphy with stapler,15
aneurysmorrhaphy with/without mesh prosthesis or metal
mesh,5,16,17 endografting,18 and ligation. However, there are
no randomised controlled trials comparing these methods.
It has been proposed that the implantation of an external
mesh prosthesis on the surface of the vein to be repaired
decreases the venous wall shear stress, thereby decreasing
the turbulent blood ﬂow, endothelial damage, and mural
thrombus formation.19,20
The aims of this study were to analyse the long-term
patency and complication rates in a cohort of 62 patients
who underwent reinforced aneurysmorrhaphy with anexternal mesh prosthesis, and to evaluate the effect of this
method in patients with high-ﬂow ﬁstulas. The assisted
primary patency of our technique (80% at 12 months) is
comparable to the assisted primary patency reported by
Berard et al. (93% at 12 months),16 who tested our method
in 33 patients. Woo et al.21 performed aneurysmorrhaphy
without an external mesh prosthesis in 19 patients, with a
median follow-up of 23 months (IQR 22 months). They
observed a median primary patency of 14 months (IQR 24
at 12 months). The effect of the external support of the
weakened vein after aneurysmorrhaphy for maintaining the
patency is not clear, and more comparative studies are
needed.
Other studies have used techniques other than aneur-
ysmorrhaphy for treating true aneurysmal AVFs. In a study
by Pasklinsky et al.,13 10 AVF aneurysms were treated.
Seven patients were treated by excision and repair with the
great saphenous vein, and three patients with excision and
repair with prosthetic material. The median follow-up was
19 months, and the primary patency rate at 12 months was
46.7%. Georgiadis et al.14 included 44 true and false
vascular access-related aneurysms in their study (26 in AV
ﬁstulas and 18 in AV grafts). Most of these patients un-
derwent resection of the aneurysm and interposition with
graft placement. The primary patency rates of the 26 AVFs
were 85% and 69% at 6 and 12 months respectively.
Almehmi and Wang3 treated 36 patients by partial
aneurysmorrhaphy, reporting an assisted primary patency
rate of 97% at 6 months; however, their mean follow-up
time was only 7.1  4.8 months. Shemesh et al.18
described the use of stent grafts to treat nine graft access
pseudoaneurysms and 11 native vein access aneurysms and
pseudoaneurysms, with a functional patency rate of 87% at
12 months and median follow-up of 15 (6.3e55.5) months.
Although their patency rate is comparable to those re-
ported here, patients with steal syndrome, aneurysms close
to the anastomosis, and large aneurysms lacking the stent
graft seal zone were excluded. Furthermore, Shemesh did
not identify patients with high-ﬂow AVFs. Other remodel-
ling salvage techniques described in the literature include
plication and lateral venorrhaphy with stapler.15,11 Unfor-
tunately, the numbers in these studies are small, the follow-
ups are short, and the patency and complication rates are
not described clearly.
The great beneﬁt of the present study is the inclusion of a
large number of patients with high-ﬂow aneurysmal AVFs
(access ﬂow >2,500 mL/minute). We conﬁrmed the effect
of reinforced aneurysmorrhaphy on ﬂow reduction in these
patients, with ﬂow decreasing from 3,968.4  1,923.8 mL/
minute before to 1,771.10  843.49 mL/minute after sur-
gery (p < .001). Only one previous study16 has proven the
effect of aneurysmorrhaphy on patients (n ¼ 16) with high-
ﬂow AVFs (ﬂow rate >1,500 mL/minute). However, in pa-
tients with ﬂow >2,500 mL/minute, the effect was not
achieved and aneurysmorrhaphy cannot be recommended
for this group of patients. For a ﬁstula with ﬂow >2,500
mL/minute located in the forearm, proximal radial artery
ligation and end-to-end anastomosis between the repaired
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is recommended. For upper-arm high-ﬂow AVF, moving the
arterial inﬂow to the forearm artery is recommended.16
In this series, only two patients needed reoperation for
repeated high-ﬂow AVF. Both cases (one brachiocephalic
and one brachiobasilic AVF) presented with brachial artery
dilatation. The primary treatment was aneurysmorrhaphy
without reduction of the anastomosis. Based on our pre-
liminary results in patients treated for high-ﬂow AVF with
aneurysmorrhaphy in the ﬁrst half of this study, including
the two patients who underwent reoperation, the policy
has been changed. Aneurysmorrhaphy with anastomosis
relocation to forearm arteries in cases with upper-arm high-
ﬂow AVF, and aneurysmorrhaphy with reduction of the
anastomosis in forearm high-ﬂow AVF are now recom-
mended. Radial artery ligation is never used. Furthermore,
it is speculated that brachial artery dilatation is an impor-
tant risk factor for re-increased ﬂow in the postoperative
period.
Although the procedures were registered prospectively in
a database, the analysis of the outcome was retrospective,
which is a limitation of this study. There are several ad-
vantages and limitations of reinforced aneurysmorrhaphy
with external mesh prosthesis. Using this technique, it is
possible to treat AVFs with multiple (concomitant) exten-
sive aneurysms. The mean maximum aneurysm diameter
was 34.47  7.33 (20e55) mm, and mean number of an-
eurysms was 2.33  0.57 (1e3). There were no aneurysmal
recurrences during follow-up. There were no recorded dif-
ﬁculties with cannulation of the reinforced vein area or any
mesh complications. The procedure was well-tolerated,
required minimal hospitalisation, and accomplished desir-
able cosmetic effect. The main disadvantage is the need for
a temporary tunnelled catheter because of the extensive
nature of the reconstructive aneurysmorrhaphy procedure.
Therefore, cannulation of the repaired ﬁstulae is inter-
rupted for 4 weeks. It is assumed that this time period was
too short for central vein stenosis or catheter infection to
develop, and no complication associated with use of the
temporary central vein catheter was recorded. In patients
treated by aneurysmorrhaphy for solitary aneurysm, the
haemodialysis should be performed by cannulation of the
non-dilated part of the vein above the aneurysmorrhaphy
segment. Infection related to the use of prosthetic material
was not seen in this study. Infection occurred in three pa-
tients (4.8%), and only one of these was conﬁrmed by
microbiology. Compared to the study by Woo et al.,21 who
used a similar technique but without external mesh pros-
thesis, the rate of infection was lower in this series (4.8% vs.
10.5%).
It is believed that this report contains the largest series of
patients with true aneurysm ﬁstula or high-ﬂow aneurysm
AVF. It is concluded that reinforced aneurysmorrhaphy with
external mesh prosthesis is an effective method for treating
true aneurysmal AVF, showing excellent long-term patency,
no aneurysmal recurrence, and a minimal infection rate.
This method appears to be suitable for high-ﬂow AVF.
Aneurysmorrhaphy with external mesh prosthesis isrecommended as a ﬁrst-line choice for the management of
extensive multiple true aneurysmal AVFs.
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